3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Acetic Acid
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled